Successful Outcomes in Patients with Exudative Age Related Macular Degeneration
Optimize the experience for your patients with Age Related Macular Degeneration (AMD) by understanding dosing frequencies, utilizing the treat-and-extend approach, and developing a standard follow-up protocol.
After completing this activity, the participant should be better able to:
- Develop a standard follow-up protocol to manage patients with exudative AMD from diagnosis through long-term care
- Determine how frequency of dosing differs between patients, identifying patients who can achieve 12-week dosing intervals with currently available therapies
- Understand the utility of the treat-and-extend approach to anti-vascular endothelial growth factor (VEFG) therapy based on measurable visual and anatomic parameters
- Identify factors that may affect patient response to therapy and select anti-VEGF therapy appropriately
- Identify best practices for optimizing the patient experience through AMD treatments and discuss lean practice models for delivery of care given the frequency of visits
Faculty Panel:
Rishi P. Singh, MD
Chair & Moderator
Peter K. Kaiser, MD
Judy E. Kim, MD
Rahul N. Khurana, MD
Philip J. Rosenfeld, MD, PhD
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Ultimate Medical Academy (UMA) and KCY Education Group. UMA is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
UMA designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support
This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc.
Faculty Disclosures
» Rishi P. Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, Novartis/Alcon, Regeneron.
» Peter K. Kaiser, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Aerpio, Alcon, Allegro, Allergan, Bayer, Biogen Idec, Boehringer Ingelheim, Galecto Biotech, Hospira, jCyte, Chengdu Kanghong, Kodiak, Novartis, Ohr Pharmaceutical, Omeros, Regeneron, Retinal Sciences, Santen, Shire, SciFluor, Spark, Stealth Biotherapeutics, Thrombogenics.
» Rahul N. Khurana, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Genentech, Regeneron.
» Judy E. Kim, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, Notal Vision.
» Philip J. Rosenfeld, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech; Contracted Research: Genentech.
Planner Disclosures
The following individuals have nothing to disclose:
» Jaya Kumar, MD, Peer reviewer; Leia Bell, UMA staff; Yaremi Koopot, CMP, KCY staff; Christine Santos, CHCP, CMP, KCY staff
